GRAY vs. APRE, BFRG, CARM, MEIP, AFMD, PIRS, NRBO, BCTX, MTVA, and NNVC
Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include Aprea Therapeutics (APRE), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), MEI Pharma (MEIP), Affimed (AFMD), Pieris Pharmaceuticals (PIRS), NeuroBo Pharmaceuticals (NRBO), BriaCell Therapeutics (BCTX), MetaVia (MTVA), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical preparations" industry.
Graybug Vision vs.
Aprea Therapeutics (NASDAQ:APRE) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by insiders. Comparatively, 7.9% of Graybug Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Graybug Vision has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Graybug Vision's return on equity.
Aprea Therapeutics received 39 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 56.70% of users gave Aprea Therapeutics an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 282.72%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Graybug Vision.
Aprea Therapeutics has higher revenue and earnings than Graybug Vision. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Aprea Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
In the previous week, Aprea Therapeutics had 4 more articles in the media than Graybug Vision. MarketBeat recorded 4 mentions for Aprea Therapeutics and 0 mentions for Graybug Vision. Aprea Therapeutics' average media sentiment score of 0.15 beat Graybug Vision's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.
Summary
Aprea Therapeutics beats Graybug Vision on 14 of the 17 factors compared between the two stocks.
Get Graybug Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Graybug Vision Competitors List
Related Companies and Tools
This page (NASDAQ:GRAY) was last updated on 1/22/2025 by MarketBeat.com Staff
Free GRAY Stock Alerts